Previous Close | 39.36 |
Open | 39.03 |
Bid | 38.84 x 10000 |
Ask | 40.39 x 20000 |
Day's Range | 39.03 - 39.03 |
52 Week Range | 35.04 - 73.20 |
Volume | |
Avg. Volume | 25 |
Market Cap | 11.419B |
Beta (5Y Monthly) | -0.06 |
PE Ratio (TTM) | 40.86 |
EPS (TTM) | N/A |
Earnings Date | N/A |
Forward Dividend & Yield | 0.98 (2.51%) |
Ex-Dividend Date | Mar 28, 2024 |
1y Target Est | N/A |
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, "Biogen") announced today that Eisai submitted to the U.S. Food and Drug Administration (FDA) a Supplemental Biologics License Application (sBLA) for monthly lecanemab-irmb (U.S. brand name: LEQEMBI®) intravenous (IV) maintenance dosing. LEQEMBI is indicated for the treatment of Alzheimer's disease (AD) in patients with
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, "Biogen") announced today that Eisai presented new data for LEQEMBI® (lecanemab-irmb) 100 mg/mL injection for intravenous (IV) use, in the Late Breaking Symposium 4 "Lecanemab for Early Alzheimer's Disease: Long-Term Outcomes, Predictive Biomarkers and Novel Subcutaneous Administration" at the 16th annual Clinical Trials